In a recent study published in Cancer Cell, researchers assessed several approaches for a circulating cell-free deoxyribonucleic acid (cfDNA)-based multi-cancer early detection (MCED) test. Defining the clinical limit of detection (LOD) based on circulating tumor allele fraction (cTAF) enables the comparison of different approaches.
An MCED test is a blood test that helps early detection of a shared cancer signal across multiple cancers using blood samples. Currently, available MCED tests have a low false-positive rate of less than 1%.
Comments are closed.